Effector CD4+ accumulating in the TME also support cancer immunity through the secretion of inflammatory cytokines (i.e., IFNγ and tumor necrosis factor alpha), production of IL-2 necessary for CD8+ T cell maintenance, and by providing help to B cells through CD40L co-stimulation (51). Here, CD8A is linked to cancer.